Today: 2 July 2026
Micron stock jumps 5% on Gen5 SSD launch as memory-price surge stays in focus
6 January 2026
1 min read

Micron stock jumps 5% on Gen5 SSD launch as memory-price surge stays in focus

New York, Jan 6, 2026, 09:49 EST — Regular session

Micron Technology, Inc. shares rose about 5% in early New York trading on Tuesday after the memory-chip maker announced a new client solid-state drive. The stock was up 5.2% at $328.27, versus a 1.7% rise for the iShares Semiconductor ETF, after closing at $312.15 on Monday.

Micron said it launched the Micron 3610, a client SSD it described as the first PCIe Gen5 drive using its G9 QLC NAND — a denser type of flash storage designed to lower cost per bit. Micron said the drive can reach sequential read speeds of up to 11,000 megabytes per second and offer up to 4 terabytes in an M.2 2230 form factor, and is already sampling with select PC makers. “The 3610 will enable ultra-thin devices that meet the growing demands of on-device AI,” said Mark Montierth, a senior vice president and general manager at Micron. Micron Technology

The product news lands as investors focus on how long the memory upcycle can last, with pricing a key swing factor for Micron’s earnings. TrendForce said DDR5 DRAM — a type of working memory used in servers and PCs — jumped 314% in the fourth quarter from a year earlier and forecast conventional DRAM contract prices rising 55% to 60% this quarter. “Prices have … risen enough” to shift buying patterns, but “not enough to suppress overall demand,” TrendForce analyst Avril Wu told Reuters. Reuters

Samsung Electronics is set to give the sector another data point on Thursday, Jan. 8, when it reports preliminary fourth-quarter results, which traders often read for signals on memory pricing. The backdrop has fueled a sharp run in memory-linked stocks: Reuters calculations based on TrendForce projections show the AI boom could drive annual growth of 29% for the wider DRAM market and 46% for high-bandwidth memory through 2027. Samsung co-CEO TM Roh has called the current supply crunch “unprecedented.” Reuters

Some analysts argue the stock still screens cheap versus its growth outlook. FactSet’s consensus calls for Micron’s revenue to grow 93% in fiscal 2026, the strongest in the S&P 500, MarketWatch reported, adding the shares trade at a forward price-to-earnings multiple of about 9.2.

Separate regulatory filings showed two Micron directors recently disposed of shares and received restricted stock units. T. Mark Liu reported disposing of 2,710 shares and receiving 53 director RSUs, while Robert H. Swan reported disposing of 4,444 shares and receiving 107 RSUs, the filings showed.

Memory remains a boom-and-bust business, and higher chip prices can pull demand forward and then snap back once inventories build. A pullback in data-center spending or a faster supply response from major suppliers could pressure pricing and margins after the latest run-up.

Micron’s next scheduled corporate events include a quarterly dividend of 11.5 cents a share due on Jan. 14 and its annual meeting on Jan. 15, where shareholders will vote on board seats and other items including an officer exculpation proposal.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Previous Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus
Next Story

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus

Go toTop